SSTR2 Radiopharmaceutical In Vivo Screen
Advance your SSTR2-targeted radiopharmaceutical programs with 35 clinically relevant patient-derived models, including neuroendocrine subtypes.
Enrollment now open
Accelerate Your SSTR2 Drug Discovery with Clinically Relevant Models
The SSTR2 Radiopharmaceutical Screen features a curated panel of 35 patient-derived models, including neuroendocrine tumors, Merkel cell carcinoma, and select small cell lung cancer (SCLC) models with confirmed SSTR2 expression. These models reflect patient tumor biology and capture heterogeneity across tumor types, enabling translationally meaningful insights for therapeutic and theranostic development.
35 Clinically Relevant Models
A curated panel of patient-derived xenograft models with SSTR2 expression, including rare neuroendocrine models
Integrated Radiochemistry & Radiopharmacology
The only CRO with both capabilities in-house, offering seamless workflows from radiolabeling througho in vivo readouts
Focused Readout
Tumor Growth Inhibition (TGI) provided as the primary endpoint for clear, actionable insights
Champions Oncology’s radiopharmacology screens reduce uncertainty with translationally relevant PDX models, enabling earlier go/no-go decisions and supporting both therapeutic and theranostic programs. As the only CRO with integrated radiochemistry and radiopharmacology in-house, we provide a seamless path from radiolabeling to in vivo insights.
-
Enrollment now open, limited availability
-
Comprehensive metadata and tumor annotations included
-
Flexible endpoints available to support biodistribution and efficacy analyses
-
No SOC arm required, rapid study initiation possible
Champions Oncology’s radiopharmacology screens reduce uncertainty with translationally relevant PDX models, enabling earlier go/no-go decisions and supporting both therapeutic and theranostic programs. As the only CRO with integrated radiochemistry and radiopharmacology in-house, we provide a seamless path from radiolabeling to in vivo insights.
-
Enrollment now open, limited availability
-
Comprehensive metadata and tumor annotations included
-
Flexible endpoints available to support biodistribution and efficacy analyses
-
No SOC arm required, rapid study initiation possible
Our screen includes 35 models across head and neck, neuroendocrine, and other clinically relevant tumor types. Each model is annotated with SSTR2 expression data and optimized for radiopharmaceutical evaluation.
|
Model
|
Tumor type
|
|---|---|
|
CTG-0258
|
Ovarian
|
|
CTG-1138
|
Ovarian
|
|
CTG-2178
|
Bladder
|
|
CTG-0199
|
SCLC
|
|
CTG-3991
|
Endometrial
|
|
CTG-1561
|
Uterine
|
|
CTG-1260
|
Breast
|
|
CTG-3346
|
Breast
|
|
CTG-3500
|
Breast
|
|
CTG-0462
|
Head and neck
|
|
CTG-3581
|
Prostate
|
|
CTG-0232
|
Merkel cell
|
|
CTG-0198
|
SCLC
|
|
CTG-1814
|
NSCLC
|
|
CTG-2930
|
Breast
|
|
CTG-1280
|
Endometrial
|
|
CTG-2441
|
Prostate
|
|
CTG-3533
|
Breast
|
|
CTG-1423
|
Ovarian
|
|
CTG-2647
|
Endometrial
|
|
CTG-3399
|
Breast
|
|
CTG-3347
|
Breast
|
|
CTG-1703
|
Ovarian
|
|
CTG-0282
|
Pancreatic
|
|
CTG-0473
|
Breast
|
|
CTG-0901
|
Head and neck
|
|
CTG-1714
|
Breast
|
|
CTG-1921
|
Thyroid
|
|
CTG-2812
|
Cervical
|
|
CTG-3140
|
Cervical
|
|
CTG-1218
|
SCLC
|
|
CTG-4320
|
Neuroendocrine
|
|
CTG-3779
|
Neuroendocrine tumor
|
|
CTG-0079
|
Colorectal
|
|
CTG-0231
|
Merkel cell
|
Get Started Today
